Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004040-10
    Sponsor's Protocol Code Number:GEIS-52
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-12-27
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-004040-10
    A.3Full title of the trial
    Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas
    Ensayo fase I-II de sunitinib y nivolumab tras tratamiento estándar en sarcomas de partes blandas y óseos avanzados
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase I-II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas
    Ensayo fase I-II de sunitinib y nivolumab en sarcomas de partes blandas y óseos avanzados
    A.4.1Sponsor's protocol code numberGEIS-52
    A.5.4Other Identifiers
    Name:ImmunosarcNumber:Immunosarc
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGrupo Español de Investigación en Sarcomas (GEIS)
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGrupo Español de Investigación en Sarcomas
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSofpromed Investigación Clínica SLU
    B.5.2Functional name of contact pointClinical Trials
    B.5.3 Address:
    B.5.3.1Street AddressC/ Ter 27 2ª planta izq. Of. 11
    B.5.3.2Town/ cityPalma de Mallorca
    B.5.3.3Post code07009
    B.5.3.4CountrySpain
    B.5.4Telephone number34971439900
    B.5.5Fax number34971570222
    B.5.6E-mailinfo@sofpromed.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Sutent
    D.2.1.1.2Name of the Marketing Authorisation holderPfizer Ltd
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSunitinib
    D.3.2Product code LO1XE04
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSUNITINIB
    D.3.9.1CAS number 557795-19-4
    D.3.9.4EV Substance CodeSUB22321
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number12.5 to 50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Opdivo
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNivolumab
    D.3.2Product code L01XC17
    D.3.4Pharmaceutical form Concentrate and solvent for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.3Other descriptive nameNIVOLUMAB
    D.3.9.4EV Substance CodeSUB122750
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and epithelioid sarcomas) or bone sarcoma (osteosarcoma/high grade bone sarcoma, Ewing sarcoma, or dedifferentiated chondrosarcoma), with metastatic/advanced and measurable disease.
    Sarcoma de partes blandas (sarcoma pleomórfico indiferenciado, sarcoma sinovial, sarcoma alveolar de partes blandas, sarcoma de células claras, angiosarcoma, hemangiosarcoma epiteliode, tumor fibrodso solitario y sarcomas epitelioides) o sarcoma óseo (osteosarcoma/sarcoma de hueso de alto grado, sarcoma de Ewing, o condrosarcoma desdiferenciado), con enfermedad metastática/avanzada y medible.
    E.1.1.1Medical condition in easily understood language
    Soft tissue sarcoma or bone sarcoma
    Sarcoma de partes blandas o sarcoma óseo
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of the sunitinib plus nivolumab combination as measured by the progression-free survival rate (PFSR) at 6 months in patientswith advanced soft tissue and bone sarcomas.
    Evaluar la eficacia de la combinación de sunitinib y nivolumab medida como la tasa de supervivencia libre de progresión (TSLP) a los 6 meses en pacientes con sarcomas de partes blandas y óseos avanzados.
    E.2.2Secondary objectives of the trial
    - To evaluate overall survival (OS).
    - To determine the objective response rate (ORR).
    - To evaluate efficacy according to immune-related response.
    - To evaluate efficacy according to Choi response.
    - To evaluate the safety profile according to CTCAE 4.0.
    - To evaluate the outcome of post protocol treatments.
    - Evaluar la supervivencia global (SG).
    - Determinar la tasa de respuesta objetiva (TRO).
    - Evaluar la eficacia según respuesta relacionada con el sistema inmune.
    - Evaluar la eficacia según respuesta Choi.
    - Evaluar el perfil de seguridad según CTCAE 4.0.
    - Evaluar el resultado de los tratamientos posteriores al protocolo.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Translational research: Soft Tissue Sarcoma and Bone Sarcoma
    Investigación traslacional: Sarcoma de partes blandas y sarcoma óseo
    E.3Principal inclusion criteria
    1. Patients must provide written informed consent prior to performance of study-specific procedures and must be willing to comply with treatment and follow-up. Informed consent must be obtained prior to start of the screening process. Procedures conducted as part of the patient’s routine clinical management (e.g. blood count, imaging tests, etc.) and obtained prior to signature of informed consent may be used for screening or baseline purposes as long as these procedures are conducted as specified in the protocol.
    2. Age: 18-80 years.
    3. Histologic diagnosis of soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and epithelioid sarcomas) or bone sarcoma (osteosarcoma/high grade bone sarcoma, Ewing sarcoma or dedifferentiated chondrosarcoma) confirmed by central pathology review. Mandatory paraffin embedded tumor blocks must be provided for all subjects without exception for biomarker analysis before treatment (first biopsy) and at end of month 3 or earlier (second biopsy).
    4. Metastatic/advanced disease in progression in the last 6 months.
    5. Patients have previously received at least anthracyclines.
    6. Measurable disease according to RECIST 1.1 criteria.
    7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
    8. Adequate hepatic, renal, cardiac, and hematologic function.
    9. Laboratory tests as follows:
    - Absolute neutrophil count ≥ 1,200/mm³
    - Platelet count ≥ 100,000/mm³
    - Bilirubin ≤ 1.5 mg/dL
    - PT and INR ≤ 1.5
    - AST and ALT ≤ 2.5 times upper limit of normal
    - Creatinine ≤ 1.5 mg/dL
    - Calcium ≤ 12 mg/dL
    - Blood glucose < 150 mg/dL
    10. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan.
    11. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and agree to use birth control measures during study treatment and for 5 months after its completion. Patients must not be pregnant or nursing at study entry. Women/men of reproductive potential must have agreed to use an effective contraceptive method.
    1. Los pacientes deben dar el consentimiento informado antes de llevar a cabo los procedimientos específicos del estudio y deben estar dispuestos a cumplir con el tratamiento y el seguimiento. El consentimiento informado se debe obtener antes de empezar con el proceso de screening. Los procedimientos hechos como parte de la práctica clínica rutinaria del paciente (ej. Recogida de sangre, test de imagen, etc.) y obtenidos antes de la firma del consentimiento informado pueden utilizarse para el screening o los objetivos de la etapa basal, siempre y cuando estos procedimientos se lleven a cabo como se especifica en el protocolo.
    2. Edad: 18-80 años.
    3. Diagnóstico histológico de sarcoma de partes blandas (sarcoma pleomórfico indiferenciado, sarcoma sinovial, sarcoma alveolar de partes blandas, sarcoma de células claras, angiosarcoma, hemangiosarcoma epiteliode, tumor fibroso solitario y sarcomas epitelioides) o sarcoma óseo (osteosarcoma/ sarcoma de hueso de alto grado, sarcoma de Ewing, o condrosarcoma desdiferenciado), confirmado por revisión patológica central. Los bloques de tumor en parafina obligatorios deben aportarse para todos los pacientes sin excepción para análisis de biomarcadores antes del tratamiento (primera biopsia) y al final del mes 3 o antes (segunda biopsia).
    4. Enfermedad metastática/avanzada en progresión en los últimos 6 meses.
    5. Pacientes que hayan recibido previamente al menos antraciclinas.
    6. Enfermedad medible según criterios RECIST 1.1.
    7. Eastern Cooperative Oncology Group (ECOG) Performance Status de 0-1.
    8. Adecuada función hepática, renal, cardiaca y hematológica.
    9. Test de laboratorio de la siguiente manera:
    - Recuento de neutrófilos absolutos ≥ 1.200/mm3
    - Recuento de plaquetas ≥ 100.000/mm3
    - Bilirrubina ≤ 1,5 mg/dL
    - PT e INR ≤ 1,5
    - AST y ALT ≤ 2,5 veces límite superior de la normalidad
    - Creatinina ≤ 1,5 mg/dL
    - Calcio ≤ 12 mg/dL
    - Glucosa en sangre < 150 mg/dL
    10. Fracción de eyección ventricular izquierda ≥ 50% por ecocardiograma o escáner MUGA.
    11. Mujeres en edad de tener hijos deben de tener un test de embarazo de sangre u orina negativo dentro de las 24 horas antes de la inclusión y tienen que estar de acuerdo con el uso de métodos anticonceptivos durante el tratamiento del estudio y por 7 meses después de su terminación. Las pacientes no pueden estar embarazadas ni amamantando a la entrada en el estudio. Mujeres y hombres con potencial reproductivo deben estar de acuerdo con el uso de métodos anticonceptivos
    E.4Principal exclusion criteria
    1. Three or more previous lines of chemotherapy for the advanced disease.
    2. Previous antiangiogenic agent, anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti PD-L2 or anti CTLA-4 antibody.
    3. Prior immune-related adverse event (Grade 3 or higher immune-related pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine, cytokine, etc.).
    4. Active, known or suspected autoimmune disease.
    5. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. 6. Uncontrolled intercurrent illness including (not limited to): symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] III/IV), unstable angina pectoris or coronary angioplasty, or stenting within 24 weeks prior to registration, unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 Grade >= 2), known psychiatric illness that would limit study compliance, intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve morphology (>= Grade 3).
    7. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. 8. Other disease or illness within the past 6 months, including any of the following:
    - Myocardial infarction
    - Severe or unstable angina
    - Coronary or peripheral artery bypass graft
    - Symptomatic congestive heart failure
    - Cerebrovascular accident or transient ischemic attack
    - Pulmonary embolism
    9. Evidence of a bleeding diathesis.
    10. Ongoing cardiac dysrhythmias > Grade 2. 11. Uncontrolled hypertension, defined as blood pressure > 150/100 mm Hg despite optimal medical therapy. 12. Psychiatric illness or social situation that would preclude study compliance. 13. Pre-existing thyroid abnormality, defined as abnormal thyroid function tests despite medication. 14. Prolonged QTc interval (i.e., QTc > 450 msec for males or QTc > 470 msec for females) on baseline ECG. 15. Hemorrhage ≥ Grade 3 in the past 4 weeks.
    16. History of allergy to study drug components.
    1. Tres o más líneas de quimioterapia previas para la enfermedad avanzada.
    2. Agente antiangiogénico previo, anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti PD-L2 o anticuerpo anti CTLA-4. 3. Antecedente de acontecimiento adverso relacionado con el sistema inmune (neumonitis, hepatitis, colitis, endocrinopatía relacionadas con el sistema inmune de grado 3 o superior) con inmunoterapia previa (por ejemplo, vacuna contra el cáncer, citoquina, etc.).
    4. Enfermedad autoinmune activa, conocida o bajo sospecha. 5. Una condición que requiera tratamiento sistémico con corticoides (>10 mg diarios de equivalentes de prednisona) u otros medicamentos inmunosupresores dentro de los 14 días antes de la administración del fármaco en estudio. Los esteroides inhalados o tópicos y las dosis adrenales de reemplazo > 10 mg diarios de equivalentes de prednisona se permiten en ausencia de enfermedad autoinmune activa.
    6. Enfermedad intercurrente no controlada incluyendo (no limitada a): insuficiencia cardíaca congestiva sintomática (ICC) (New York Heart Association [NYHA] III/IV), angina de pecho inestable o angioplastia coronaria, o stent en las 24 semanas previas al registro, arritmia cardíaca inestable (disritmias cardiacas en curso según NCI CTCAE versión 4.0 Grado >=2), enfermedad psiquiátrica conocida que limitaría el cumplimiento del estudio, desfibriladores intra cardíacos, metástasis cardíacas conocidas o morfología valvular cardiaca anormal (>= Grado 3).
    7. Test positivo del antígeno de superficie del virus de la hepatitis B (HBV sAg) o del ácido ribonucleico del virus de la hepatitis C (Anticuerpo HCV) que indica infección crónica o aguda.
    8. Otra enfermedad en los últimos 6 meses, incluyendo cualquiera de las siguientes:
    - Infarto de miocardio
    - Angina severa o inestable
    - Injerto de marcapasos en arteria coronaria o periférica
    - Fallo cardíaco congestivo sintomático
    - Accidente cerebrovascular o ataque isquémico transitorio
    - Embolismo pulmonar
    9. Evidencia de una diátesis hemorrágica.
    10. Disritmias cardiacas en curso < Grado 2.
    11. Hipertensión incontrolada, definida como presión arterial >150/100 mmHg a pesar de una óptima terapia médica.
    12. Enfermedad psiquiátrica o situación social que no permitiría cumplimiento del estudio.
    13. Preexistencia de anormalidades del tiroides, definidas como pruebas anormales de la función tiroidea a pesar de la medicación.
    14. Intervalo QTc prolongado (QTc > 450 ms para hombres o QTc > 470 ms para
    mujeres) en el ECG basal.
    15. Hemorragia ≥ Grado 3 en las 4 semanas previas.
    16. Historial de alergia a los componentes de la medicación de estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Progression-free survival rate (PFSR): Efficacy measured by the PFSR at 6 months according to RECIST 1.1. PFSR at 6 months is defined as the percentage of patients who did not experience progression or death due to any cause since the first dose of experimental treatment until month 6 after treatment initiation.
    Tasa de supervivencia libre de progresión (TSLP): Eficacia medida por la TSLP a los 6 meses según RECIST 1.1. TSLP a los 6 meses se define como el porcentaje de pacientes que no experimentaron progresión o muerte debida a cualquier causa desde la primera dosis del tratamiento experimental hasta el mes 6 después del inicio del tratamiento.
    E.5.1.1Timepoint(s) of evaluation of this end point
    At 6 months
    A los 6 meses
    E.5.2Secondary end point(s)
    - Overall survival (OS): OS is defined as the time between the date of first dose and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.
    - Objective Response Rate (ORR): ORR is defined as the number of subjects with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) divided by the number of response evaluable subjects (according to RECIST 1.1 criteria).
    - Efficacy measured through immune-related response criteria.
    - Efficacy measured through tumor response according to Choi criteria. The evaluation criteria will be based on the identification of target lesions in baseline and their follow-up until tumor progression.
    - Safety profile of the experimental treatment, through assessment of adverse event type, incidence, severity, time of appearance, related causes, as well as physical explorations and laboratory tests. Toxicity will be graded and tabulated by using CTCAE 4.0.
    - Clinical outcomes of post protocol treatments assessed by observation of such treatments in follow-up stage.
    - Supervivencia global (SG): La SG se define como el tiempo entre la fecha de la primera dosis y la fecha de muerte por cualquier causa. La SG se censurará en la última fecha en la que se supo que el paciente estaba vivo.
    - Tasa de respuesta objetiva (TRO): TRO se define como el número de sujetos con mejor respuesta global de Respuesta Completa (RC) o Respuesta Parcial (RP) dividido por el número de sujetos evaluables por la respuesta (según criterios RECIST 1.1).
    - Eficacia medida mediante criterios de respuesta relacionados con el sistema inmune.
    - Eficacia medida mediante la respuesta del tumor según criterios Choi. Los criterios de evaluación se basarán en la identificación de las lesiones diana en el tiempo basal y su seguimiento hasta la progresión del tumor.
    - Perfil de seguridad del tratamiento experimental, mediante la evaluación del acontecimiento adverso: tipo, incidencia, gravedad, tiempo de aparición, causas relacionadas, así como las exploraciones físicas y las pruebas de laboratorio. La toxicidad se clasificará y tabulará utilizando CTCAE 4.0.
    - Los resultados clínicos de los tratamientos posteriores al protocolo serán evaluados mediante observación de tales tratamientos en la fase de seguimiento.
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Overall survival (OS): At 2 years
    - Objective Response Rate (ORR): Every 3 months
    - Efficacy measured through immune-related response criteria: At the end of treatment
    - Efficacy measured through tumor response according to Choi criteria: Every 3 months
    - Safety profile: At the end of treatment
    - Clinical outcomes: During follow-up
    - Supervivencia global (SG): A los 2 años
    - Tasa de respuesta objetiva (TRO): Cada 3 meses
    - Eficacia medida mediante criterios de respuesta relacionados con el sistema inmune: Al final del tratamiento
    - Eficacia medida mediante la respuesta del tumor según criterios Choi: Cada 3 meses
    - Perfil de seguridad: Al final del tratamiento
    - Resultados clínicos: Durante el seguimiento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Safety
    Seguridad
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA5
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will be considered closed from a normative point of view after data on primary and secondary variables are sufficiently prepared for its initial publication.
    El estudio se considerará cerrado desde un punto de vista normativo después de que los datos relacionados con las variables principales y secundarias estén lo suficientemente preparados para su publicación inical
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 55
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 75
    F.4.2.2In the whole clinical trial 75
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-02-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-02-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:55:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA